What is JNJ's current stock price?

As of now, JNJ is trading at $219.57, with a daily change of +0.47%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

JNJ Stock Analysis & IQ Rating | Johnson & Johnson

JNJ

Johnson & Johnson

$219.57

+$1.02 | +0.47%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$219.75

MKT CAP

$529.01B

52W Low

$141.5

VOL

$7.62M

P/E Ratio

21.19

AVG VOL

$8.24M

RSI

71.32

TREND

Uptrend

JNJ Stock IQ

Login to see Johnson & Johnson (JNJ) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

JNJ Target Price

Login to display

Strengths

JNJ Rewards

Earnings are forecast to grow

JNJ Rewards

Upgraded on attractively valued

JNJ Rewards

Investors confidence is positive

JNJ Rewards

Outperform the market

Technical Indicators

JNJ Technical Indicators

Overbought

JNJ Technical Indicators

Aroon crosses up

JNJ Price Performance

$210.33 (+4.39%)

$193.72 (+13.34%)

$179.29 (+22.47%)

$152.15 (+44.31%)

1year

6month

3month

1month

JNJ Risk Level

JNJ has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

Low

LOW

HIGH

JNJ Analysts Opinion

JNJ overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

JNJ Analysts Opinion

JNJ Analysts opinion is negative and it remained unchanged from the past 3 months

JNJ Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

84%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

83%

79%

JNJ Street Sentiment

JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook

JNJ Performance Sentiment

Sentiments overview associated with JNJ events and the stock performance.

84%

13%

Positive

Negative

47 out of 56
events present

7 out of 56
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$218.55

Resistance
Price

$201.27

Current Price Range

$218.55

Show methods +

Linked to JNJ

IQ

Close Price

Change

NBTX

N/A

21.17

-1.67%

BLTE

2.20

149.61

-2.65%

ANNX

2.30

6.16

-7.78%

SNDX

2.45

20.67

-3.59%

REGN

4.14

741.92

-1.62%

Recently Viewed

Close Price

Change

JNJ

Johnson & Johnson

219.57

+0.47%

REGN

Regeneron Pharma

741.92

-1.62%

JAKK

JAKKS Pacific

19.55

+1.35%

NRIM

Northrim BanCorp Inc

29.00

+4.17%

TMUS

T-Mobile

190.66

-0.71%

JNJ Latest Analysis +

Exploring Analyst Estimates for Johnson & Johnson (JNJ) Q4 Earnings Beyond Revenue and EPS. Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended December 2025 looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Today

$219.57 | +0.47%

Earnings

Johnson & Johnson Drug Slows Blood Cancer Extends Survival In Pretreated Patients. ) shared topline results from the investigational Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) a type of blood cancer.The MajesTEC-9 study evaluates the efficacy and safety of Tecvayli versus the standard of care of pomalidomide bortezomib and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who have received .MajesTEC-9 is the second Phase

Today

$219.57 | +0.47%

Activity

Johnson & Johnson Reaches Analyst Target Price. In recent trading shares of Johnson &. Johnson (Symbol: JNJ) have crossed above the average analyst 12-month target price of $213.83 changing hands for $218.61/share. When a stock reaches the target an analyst has set the analyst logically has two ways to react: downgrade

Today

$219.57 | +0.47%

Potential

Rating

Johnson & Johnsons TECVAYLI Shows 71% Risk Reduction In Phase 3 MajesTEC-9 Multiple Myeloma Study . (RTTNews) - Johnson & Johnson (JNJ) announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy. The study demonstrated that TECVAYLI reduced the risk of disease progression or death by 71% and the risk of death

Today

$219.57 | +0.47%

Activity

J&Js Tecvayli shows promise as a second-line multiple myeloma treatment.

Wed Jan 14, 2026

$218.55 | +2.29%

Activity

Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth. Johnson & Johnson (JNJ) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wed Jan 14, 2026

$218.55 | +2.29%

Earnings

Noteworthy Wednesday Option Activity: LYFT VLO JNJ. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Lyft Inc (Symbol: LYFT) where a total volume of 42269 contracts has been traded thus far today a contract volume which is representative of approximately 4.2

Wed Jan 14, 2026

$218.55 | +2.29%

Momentum

Heres What Lifted Johnson & Johnson (JNJ) in Q4. Mar Vista Investment Partners LLC an investment management company released its Mar Vista United States Quality Strategy fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its [….]

Tue Jan 13, 2026

$213.65 | +1.87%

Momentum

Whats Powering J&Js MedTech Growth Ahead of Q4 Release?. JNJs MedTech unit is gaining momentum from cardiovascular strength and new products even as China pressure lingers into the next quarter.

Tue Jan 13, 2026

$213.65 | +1.87%

Activity

Momentum

Potential

Delaware top court reduces Johnson & Johnsons $1B loss from robotics takeover - report.

Tue Jan 13, 2026

$213.65 | +1.87%

Activity

FAQ About JNJ Stock Insights

What is JNJ current stock price?

What are JNJ stock strengths?

What is JNJ Risk Level?

What is JNJ market cap and volume?

What is JNJ current Stock IQ?

Should I buy JNJ stock right now?

Is JNJ a Strong Buy right now?

What does a 'Strong Buy' rating mean for JNJ?

What does a 'Strong Sell' rating mean for JNJ?

What factors influence JNJ's Stock IQ?

Explore our JNJ Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored JNJ Stock Strategies
Effective Risk Management

FIND US ON

Receive our JNJ Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

JNJ

Johnson & Johnson

Set Alerts

Current Price

$219.57

+$1.02 | +0.47%

52W High

$219.75

MKT CAP

$529.01B

52W Low

$141.5

VOL

$7.62M

P/E Ratio

21.19

AVG VOL

$8.24M

RSI

71.32

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

JNJ Stock IQ

Login to unlock Johnson & Johnson (JNJ) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

JNJ Rewards

Earnings are forecast to grow

JNJ Rewards

Upgraded on attractively valued

JNJ Rewards

Investors confidence is positive

JNJ Rewards

Outperform the market

Technical Indicators

JNJ Technical Indicators

Overbought

JNJ Technical Indicators

Aroon crosses up

Linked to JNJ

Symbol

IQ

Close

Change

NBTX

N/A

21.17

-1.67%

BLTE

2.20

149.61

-2.65%

ANNX

2.30

6.16

-7.78%

SNDX

2.45

20.67

-3.59%

REGN

4.14

741.92

-1.62%

JNJ Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

84%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

83%

79%

JNJ Street Sentiment

JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook

JNJ Risk Level

JNJ has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

Low

LOW

HIGH

JNJ Performance Sentiment

Sentiments overview associated with JNJ events and the stock performance.

84%

13%

Positive

Negative

47 out of 56
events present

7 out of 56
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$218.55

Resistance
Price

$201.27

Current Price Range

$218.55

Show methods +

JNJ Latest Analysis

Exploring Analyst Estimates for Johnson & Johnson (JNJ) Q4 Earnings Beyond Revenue and EPS. Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended December 2025 looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Today

$219.57 | +0.47%

Earnings

Johnson & Johnson Drug Slows Blood Cancer Extends Survival In Pretreated Patients. ) shared topline results from the investigational Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) a type of blood cancer.The MajesTEC-9 study evaluates the efficacy and safety of Tecvayli versus the standard of care of pomalidomide bortezomib and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who have received .MajesTEC-9 is the second Phase

Today

$219.57 | +0.47%

Activity

Johnson & Johnson Reaches Analyst Target Price. In recent trading shares of Johnson &. Johnson (Symbol: JNJ) have crossed above the average analyst 12-month target price of $213.83 changing hands for $218.61/share. When a stock reaches the target an analyst has set the analyst logically has two ways to react: downgrade

Today

$219.57 | +0.47%

Potential

Rating

Johnson & Johnsons TECVAYLI Shows 71% Risk Reduction In Phase 3 MajesTEC-9 Multiple Myeloma Study . (RTTNews) - Johnson & Johnson (JNJ) announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy. The study demonstrated that TECVAYLI reduced the risk of disease progression or death by 71% and the risk of death

Today

$219.57 | +0.47%

Activity

J&Js Tecvayli shows promise as a second-line multiple myeloma treatment.

Wed Jan 14, 2026

$218.55 | +2.29%

Activity

Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth. Johnson & Johnson (JNJ) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wed Jan 14, 2026

$218.55 | +2.29%

Earnings

Noteworthy Wednesday Option Activity: LYFT VLO JNJ. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Lyft Inc (Symbol: LYFT) where a total volume of 42269 contracts has been traded thus far today a contract volume which is representative of approximately 4.2

Wed Jan 14, 2026

$218.55 | +2.29%

Momentum

Heres What Lifted Johnson & Johnson (JNJ) in Q4. Mar Vista Investment Partners LLC an investment management company released its Mar Vista United States Quality Strategy fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its [….]

Tue Jan 13, 2026

$213.65 | +1.87%

Momentum

Whats Powering J&Js MedTech Growth Ahead of Q4 Release?. JNJs MedTech unit is gaining momentum from cardiovascular strength and new products even as China pressure lingers into the next quarter.

Tue Jan 13, 2026

$213.65 | +1.87%

Activity

Momentum

Potential

Delaware top court reduces Johnson & Johnsons $1B loss from robotics takeover - report.

Tue Jan 13, 2026

$213.65 | +1.87%

Activity

Discover JNJ Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of JNJ. We're here to help you make informed investment decisions today.

FIND US ON

Receive our JNJ Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

JNJ Stock trends

JNJ Stock performance

JNJ Stock analysis

JNJ investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing JNJ

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing JNJ

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

JNJ Stock Analysis & IQ Rating | Johnson & Johnson

JNJ Stock IQ

JNJ Target Price

JNJ Risk Level

JNJ Analysts Opinion

JNJ Street Sentiment

JNJ Performance Sentiment

Technical Price Levels

Explore our JNJ Stock insights

Receive our JNJ Daily Alerts

JNJ Street Sentiment

JNJ Risk Level

Technical Price Levels

Discover JNJ Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of JNJ. We're here to help you make informed investment decisions today.

Receive our JNJ Daily Alerts

JNJ Alerts